Chondromodulin‑I suppresses tumorigenesis of human osteosarcoma cells

Lin,Xiangbo; Wang,Lijun; Wang,Faming

doi:10.3892/mmr.2017.7629

Chondromodulin‑I suppresses tumorigenesis of human osteosarcoma cells

Authors:
- Xiangbo Lin
- Lijun Wang
- Faming Wang
View Affiliations

Affiliations: Department of Orthopedics, Rizhao People's Hospital, Rizhao, Shandong 276826, P.R. China, Department of Neurosurgery, Rizhao People's Hospital, Rizhao, Shandong 276826, P.R. China, Department of Orthopedics, Wulian People's Hospital, Rizhao, Shandong 262300, P.R. China
Published online on: September 26, 2017 https://doi.org/10.3892/mmr.2017.7629
Pages: 8542-8548

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma is the most common type of bone cancer, and accounts for ~3% of cancers that occurring in children. Chondromodulin‑I (ChM-I) is a 25 kDa glycoprotein that is expressed mainly in cartilage. ChM-I demonstrates anti‑angiogenic activity and has been suggested to inhibit endothelial cells from invading cartilage, and then has been shown to be an inhibitor of tumorigenesis. However, it remains unclear if ChM‑I has any direct anti‑tumorigenesis role on osteosarcoma. Therefore, the present study aimed to identify whether ChM‑I has any direct inhibit effect on human osteosarcoma cells. A bromodeoxyuridine incorporation assay was performed on the Saos‑2 human osteosarcoma cell line treated with or without recombinant human ChM‑I, to evaluate its impact on DNA synthesis. An adenovirus carrier for the expression of ChM‑I was constructed and transfected into tumor cells in vitro to evaluate the effect of ChM‑I on tumor cells. Additionally, ChM‑I was knocked down by using small interfering RNA to downregulate the expression of ChM‑I. Cell invasion, migration and cell‑colony formation assays, and xenograft tumor experiments were performed to evaluate the effects of ChM‑I on tumor cells in vitro and in vivo. The results demonstrated that ChM‑I could suppress DNA synthesis of human osteosarcoma cells, and it also exerted an inhibitory effect on the proliferation and colony formation abilities of human osteosarcoma cells. In addition, ChM‑I inhibited cell invasion and migration in vitro and suppressed osteosarcoma cell growth significantly in vivo. In conclusion, ChM‑I directly suppressed the proliferation and growth of osteosarcoma cells in an anchorage‑independent manner, and may therefore be a promising drug for the treatment of osteosarcoma.

View Figures

View References

1	Kansara M, Teng MW, Smyth MJ and Thomas DM: Translational biology of osteosarcoma. Nat Rev Cancer. 14:722–735. 2014. View Article : Google Scholar : PubMed/NCBI
2	Parkin DM, Pisani P and Ferlay J: Global cancer statistics. CA Cancer J Clin. 49:33–64. 1999. View Article : Google Scholar : PubMed/NCBI
3	Bielack S, Kempf-Bielack B, Von Kalle T, Schwarz R, Wirth T, Kager L and Whelan J: Controversies in childhood osteosarcoma. Minerva Pediatr. 65:125–48. 2013.PubMed/NCBI
4	Moore DD and Luu HH: Osteosarcoma. Cancer Treat Res. 162:65–92. 2014. View Article : Google Scholar : PubMed/NCBI
5	Ottaviani G and Jaffe N: The epidemiology of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
6	Isakoff MS, Bielack SS, Meltzer P and Gorlick R: Osteosarcoma: Current treatment and a collaborative pathway to success. J Clin Oncol. 33:3029–3035. 2015. View Article : Google Scholar : PubMed/NCBI
7	Fan Z, Patel S, Lewis VO, Guadagnolo BA and Lin PP: Should High-grade extraosseous osteosarcoma Be treated with multimodality therapy like other soft tissue sarcomas? Clin Orthop Relat Res. 473:3604–3611. 2015. View Article : Google Scholar : PubMed/NCBI
8	Jones KB, Ferguson PC, Lam B, Biau DJ, Hopyan S, Deheshi B, Griffin AM, White LM and Wunder JS: Effects of neoadjuvant chemotherapy on image-directed planning of surgical resection for distal femoral osteosarcoma. J Bone Joint Surg Am. 94:1399–1405. 2012. View Article : Google Scholar : PubMed/NCBI
9	Peng N, Gao S, Guo X, Wang G, Cheng C, Li M and Liu K: Silencing of VEGF inhibits human osteosarcoma angiogenesis and promotes cell apoptosis via VEGF/PI3K/AKT signaling pathway. Am J Transl Res. 8:1005–1015. 2016.PubMed/NCBI
10	Dossi R, Frapolli R, Di Giandomenico S, Paracchini L, Bozzi F, Brich S, Castiglioni V, Borsotti P, Belotti D, Uboldi S, et al: Antiangiogenic activity of trabectedin in myxoid liposarcoma: Involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1. Int J Cancer. 136:721–729. 2015.PubMed/NCBI
11	Miura S, Kondo J, Takimoto A, Sano-Takai H, Guo L, Shukunami C, Tanaka H and Hiraki Y: The N-terminal cleavage of chondromodulin-I in growth-plate cartilage at the hypertrophic and calcified zones during bone development. PLoS One. 9:e942392014. View Article : Google Scholar : PubMed/NCBI
12	Aoyama T, Okamoto T, Fukiage K, Otsuka S, Furu M, Ito K, Jin Y, Ueda M, Nagayama S, Nakayama T, et al: Histone modifiers, YY1 and p300, regulate the expression of cartilage-specific gene, chondromodulin-I, in mesenchymal stem cells. J Biol Chem. 285:29842–29850. 2010. View Article : Google Scholar : PubMed/NCBI
13	Hiraki Y and Shukunami C: Chondromodulin-I as a novel cartilage-specific growth-modulating factor. Pediatr Nephrol. 14:602–605. 2000. View Article : Google Scholar : PubMed/NCBI
14	Hiraki Y, Inoue H, Iyama K, Kamizono A, Ochiai M, Shukunami C, Iijima S, Suzuki F and Kondo J: Identification of chondromodulin I as a novel endothelial cell growth inhibitor. Purification and its localization in the avascular zone of epiphyseal cartilage. J Biol Chem. 272:32419–32426. 1997. View Article : Google Scholar : PubMed/NCBI
15	Yukata K, Matsui Y, Shukunami C, Takimoto A, Hirohashi N, Ohtani O, Kimura T, Hiraki Y and Yasui N: Differential expression of Tenomodulin and Chondromodulin-1 at the insertion site of the tendon reflects a phenotypic transition of the resident cells. Tissue Cell. 42:116–120. 2010. View Article : Google Scholar : PubMed/NCBI
16	Oshima Y, Sato K, Tashiro F, Miyazaki J, Nishida K, Hiraki Y, Tano Y and Shukunami C: Anti-angiogenic action of the C-terminal domain of tenomodulin that shares homology with chondromodulin-I. J Cell Sci. 117:2731–2744. 2004. View Article : Google Scholar : PubMed/NCBI
17	Tsai AC, Pan SL, Sun HL, Wang CY, Peng CY, Wang SW, Chang YL, Kuo SC, Lee KH and Teng CM: CHM-1, a new vascular targeting agent, induces apoptosis of human umbilical vein endothelial cells via p53-mediated death receptor 5 up-regulation. J Biol Chem. 285:5497–5506. 2010. View Article : Google Scholar : PubMed/NCBI
18	Hsu SC, Yang JS, Kuo CL, Lo C, Lin JP, Hsia TC, Lin JJ, Lai KC, Kuo HM, Huang LJ, et al: Novel quinolone CHM-1 induces apoptosis and inhibits metastasis in a human osterogenic sarcoma cell line. J Orthop Res. 27:1637–1644. 2009. View Article : Google Scholar : PubMed/NCBI
19	Zhang P, Wang Y, Xu P, Song S, Zhu X, Shi Z, Gao S and Feng X: Chondromodulin-1 functions as a tumor suppressor in gastric adenocarcinoma. Int J Oncol. 47:941–950. 2015. View Article : Google Scholar : PubMed/NCBI
20	Shao J, Gan L and Wang J: Transfection of chondromodulin I into human breast cancer cells and its effect on the inhibition of cancer cell growth. Mol Med Rep. 13:4303–4308. 2016. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Roloff F, Ziege S, Baumgärtner W, Wewetzer K and Bicker G: Schwann cell-free adult canine olfactory ensheathing cell preparations from olfactory bulb and mucosa display differential migratory and neurite growth-promoting properties in vitro. BMC Neurosci. 14:1412013. View Article : Google Scholar : PubMed/NCBI
23	Franken NA, Rodermond HM, Stap J, Haveman J and van Bree C: Clonogenic assay of cells in vitro. Nat Protoc. 1:2315–2319. 2006. View Article : Google Scholar : PubMed/NCBI
24	Li P, Chen X, Su L, Li C, Zhi Q, Yu B, Sheng H, Wang J, Feng R, Cai Q, et al: Epigenetic silencing of miR-338-3p contributes to tumorigenicity in gastric cancer by targeting SSX2IP. PLoS One. 8:e667822013. View Article : Google Scholar : PubMed/NCBI
25	Shingu T, Holmes L, Henry V, Wang Q, Latha K, Gururaj AE, Gibson LA, Doucette T, Lang FF, Rao G, et al: Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells. J Transl Med. 14:462016. View Article : Google Scholar : PubMed/NCBI
26	Yang Z, Li X, Yang Y, He Z, Qu X and Zhang Y: Long noncoding RNAs in the progression, metastasis, and prognosis of osteosarcoma. Cell Death Dis. 7:e23892016. View Article : Google Scholar : PubMed/NCBI
27	PDQ Pediatric Treatment Editorial Board, . Osteosarcoma and Malignant Fibrous Histiocytoma of Bone Treatment (PDQ^®)PDQ Cancer Information Summaries [Internet]. Health Professional Version. National Cancer Institute (US); Bethesda: 2002
28	Abarrategi A, Tornin J, Martinez-Cruzado L, Hamilton A, Martinez-Campos E, Rodrigo JP, González MV, Baldini N, Garcia-Castro J and Rodriguez R: Osteosarcoma: Cells-of-Origin, cancer stem cells, and targeted therapies. Stem Cells Int. 2016:36317642016. View Article : Google Scholar : PubMed/NCBI
29	Li CJ, Liu XZ, Zhang L, Chen LB, Shi X, Wu SJ and Zhao JN: Advances in Bone-targeted drug delivery systems for neoadjuvant chemotherapy for osteosarcoma. Orthop Surg. 8:105–110. 2016. View Article : Google Scholar : PubMed/NCBI
30	Friebele JC, Peck J, Pan X, Abdel-Rasoul M and Mayerson JL: Osteosarcoma: A meta-analysis and review of the literature. Am J Orthop (Belle Mead NJ). 44:547–553. 2015.PubMed/NCBI
31	Li S, Sun W, Wang H, Zuo D, Hua Y and Cai Z: Research progress on the multidrug resistance mechanisms of osteosarcoma chemotherapy and reversal. Tumour Biol. 36:1329–1338. 2015. View Article : Google Scholar : PubMed/NCBI
32	Dass CR and Choong PF: Gene therapy for osteosarcoma: Steps towards clinical studies. J Pharm Pharmacol. 60:405–413. 2008. View Article : Google Scholar : PubMed/NCBI
33	Clark JC, Dass CR and Choong PF: A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol. 134:281–297. 2008. View Article : Google Scholar : PubMed/NCBI
34	Kerbel RS: Tumor angiogenesis: Past, present and the near future. Carcinogenesis. 21:505–515. 2000. View Article : Google Scholar : PubMed/NCBI
35	Maione F and Giraudo E: Tumor angiogenesis: Methods to analyze tumor vasculature and vessel normalization in mouse models of cancer. Methods Mol Biol. 1267:349–365. 2015. View Article : Google Scholar : PubMed/NCBI
36	Kubota Y: Tumor angiogenesis and anti-angiogenic therapy. Keio J Med. 61:47–56. 2012. View Article : Google Scholar : PubMed/NCBI
37	Klinger P, Surmann-Schmitt C, Brem M, Swoboda B, Distler JH, Carl HD, von der Mark K, Hennig FF and Gelse K: Chondromodulin 1 stabilizes the chondrocyte phenotype and inhibits endochondral ossification of porcine cartilage repair tissue. Arthritis Rheum. 63:2721–2731. 2011. View Article : Google Scholar : PubMed/NCBI
38	Miura S, Kondo J, Kawakami T, Shukunami C, Aimoto S, Tanaka H and Hiraki Y: Synthetic disulfide-bridged cyclic peptides mimic the anti-angiogenic actions of chondromodulin-I. Cancer Sci. 103:1311–1318. 2012. View Article : Google Scholar : PubMed/NCBI
39	Liang CC, Park AY and Guan JL: In vitro scratch assay: A convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2:329–333. 2007. View Article : Google Scholar : PubMed/NCBI